

Unprecedented clinical value

QuantiFERON®-TB Gold Plus –
original CD8 T cell technology



— Sample to Insight —



It's time to test and treat TB

Testing and treating latent TB infection is the most effective way to prevent transmission of TB and eventually eradicate the disease.

The global impact of TB (1):

10 million



fell ill with TB in 2018



1.5 million

people died

from TB in 2018

Every minute...



3 lives
are lost to TB



18 people
fall ill with TB



6 cases
of TB go undiagnosed

Systematic TB testing saves lives


The WHO and ECDC recommend systematic latent TB testing for key risk groups (2, 3):




Receiving Anti
TNF treatment



People living
with HIV



Contact
tracing



Children
under 5

Conditional testing and treatment is also recommended for healthcare workers and communal settings:



Healthcare
workers



Immigrants



Prisoners and
community setting

QuantiFERON-TB Gold Plus

Designed to meet the needs of your practice.





- Single-visit
- Unaffected by the BCG vaccine
- Simple blood draw and lab-based testing, with rapid and objective interpretation
- Flexible collection options of undiluted whole blood into QFT®-Plus Blood Collection Tubes or into a single lithium or sodium heparin tube
- The only IGRA enabling measurement of CD8 T cell responses

For 1000 BCG-vaccinated patients who are not infected (4, 5):

TST positive
410 (41%)

QFT-Plus positive
20 (2%)



Unnecessary treatment
Costly follow-up

Now you can see the full picture

CD4 and CD8 T cells both play a critical role in the immune response to TB infection. Thanks to its unique and proprietary design, QuantiFERON-TB Gold Plus is the only test that can elicit distinct CD4 and CD8 T cell responses from whole blood patient samples.

The World Health Organization has acknowledged the potential for additional clinical insights using QFT-Plus (6):



“A new generation assay, the QuantiFERON-TB Plus has been developed to stimulate gamma interferon production by both CD4 and CD8 T-cells. First results indicate that the CD8 T-cell response may be able to identify people at greater risk of progression to active TB.”

Table 1. Features and benefits of the QFT-Plus test

| Feature | Benefit |
|---|---|
| Proprietary antigens stimulating both CD4 and CD8 T cell responses | Studies show that CD8 T cell responses are detectable in active TB subjects with HIV co-infection and in young children (7–9) |
| Differentiation of CD8 T cell responses, which may be associated with recent TB exposure and may be more frequently detected in patients with active TB disease (10–12) | Potential to provide additional clinical information supporting patient surveillance and treatment decisions |
| Flexible blood collection options <ul style="list-style-type: none">• Collect directly into the QFT-Plus tubes• Collect to a single Lithium or Sodium Heparin tube | Choose a collection method that fits your practice, including protocols allowing up to 53 hours for sample handling prior to incubation |

Research studies suggest potential new clinical insights based on CD8 T cell responses

Two meta-analyses on QFT-Plus performance confirm increased test sensitivity compared to the previous generation of the QFT test, attributing this improvement to the CD8 T cell technology in the TB2 tube (13, 14).



“The inclusion of TB2 peptides increased the sensitivity of QFT-Plus assay without affecting the specificity of the test.” (14)

In two research studies analyzing test performance in patients co-infected with HIV, QFT-Plus sensitivity for active TB was found to be unaffected by HIV-status (15, 16).



“The assay’s overall sensitivity was maintained, regardless of HIV status.” (15)

Research studies also indicate that the presence and strength of the CD8 T cell response may provide new insights when considering a patient’s risk of recent TB infection and disease (7, 17).



“[The] difference between TB2 and TB1 was higher in smear-positive [pulmonary tuberculosis] compared to smear-negative patients.” (7)



“[Our research study] suggests a role for the differential value between the two tubes as a proxy for recent infection.” (17)

For more information visit
www.QuantiFERON.com

References:

1. WHO. (2019) Global tuberculosis report 2019.
2. WHO. (2020) WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment.
3. ECDC. (2018) Programmatic management of latent tuberculosis infection in the European Union.
4. *QuantiFERON-TB Gold Plus (QFT-Plus) ELISA Package Insert*. Rev. 06. April 2019.
5. Pai, M., Zwerling, A., Menzies, D. (2008) Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. *Ann. Intern. Med.* **149**, 177–184.
6. WHO. (2017) Global tuberculosis report 2017.
7. Barcellini, L. et al. (2016) First independent evaluation of QuantiFERON-TB Plus performance. *Eur. Respir. J.* **47**, 1587.
8. Chicchio, T. et al. (2014) Polyfunctional T-cells and effector memory phenotype are associated with active TB in HIV-infected patients. *J. Infect.* **69**, 533.
9. Lanicioni, C. et al. (2012) CD8+ T cells provide an immunologic signature of tuberculosis in young children. *Am. J. Respir. Crit. Care Med.* **185**, 206.
10. Day, C.L. et al. (2011) Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load. *J. Immunol.* **187**, 2222.
11. Rozot, V. et al. (2013) Mycobacterium tuberculosis-specific CD8+ T cells are functionally and phenotypically different between latent infection and active disease. *Eur. J. Immunol.* **43**, 1568.
12. Nikolova, M. et al. (2013) Antigen-specific CD4- and CD8-positive signatures in different phases of Mycobacterium tuberculosis infection. *Diagn. Microbiol. Infect. Dis.* **75**, 277.
13. Sotgiu, G. et al. (2019) QuantiFERON TB Gold Plus for the diagnosis of tuberculosis: a systematic review and meta-analysis. *J. Infect.* **79**, 444–453.
14. Pourakbari, B. et al. (2019) Comparison of the QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube interferon-gamma release assays: a systematic review and meta-analysis. *Adv. Med. Sci.* **64**, 437–443.
15. Telesinghe, L. et al. (2017) The sensitivity of the QuantiFERON-TB Gold Plus assay in Zambian adults with active tuberculosis. *Int. J. Tuberc. Lung Dis.* **21**, 690–696.
16. Petruccioli, E., et al. (2020) Effect of HIV-infection on QuantiFERON-plus accuracy in patients with active tuberculosis and latent infection. *J. Infect.* **80**, 536–546.
17. Barcellini, L. et al. (2016) First evaluation of QuantiFERON-TB Gold Plus performance in contact screening. *Eur. Resp. J.* **48**, 1411–1419.

QFT-Plus is an in vitro diagnostic aid for detection of *Mycobacterium tuberculosis* infection. QFT-Plus is an indirect test for *M. tuberculosis* infection (including disease) and is intended for use in conjunction with risk assessment, radiography, and other medical and diagnostic evaluations. QFT-Plus package inserts as well as up-to-date licensing information and product-specific disclaimers can be found at www.QuantiFERON.com.

Trademarks: QIAGEN®, Sample to Insight®, QFT®, QuantiFERON® (QIAGEN Group). Registered names, trademarks, etc. used in this document, even when not specifically marked as such, are not to be considered unprotected by law.

1122317 08/2020 PROM-16632-001 © 2020, QIAGEN, all rights reserved.